Topic: American Society of Hematology (ASH)
This year’s ASH saw multiple presentations on BCMA-targeting drugs, but Jefferies says Bluebird’s CAR-T bb2121 “is still leading the pack.”
Just over a week ago, Spark Therapeutics was riding high on positive data for its hemophilia B gene therapy. It’s now fallen back to earth after spooking investors with the results of a trial in hemophilia A.
Phase 2 data presented at ASH 2017 suggests that Roche's high expectations for its antibody-drug conjugate for non-Hodgkin lymphoma could be justified.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.